Clarivate Acquires Bioinfogate For Undisclosed Terms To Expand Drug R&D Intelligence


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • Clarivate PLC (NYSE:CLVT) acquired Bioinfogate, an analytics solutions provider in the life sciences and producer of the OFF-X portal. 
  • The financial terms of the transaction remain undisclosed. 
  •  The acquisition of Bioinfogate will fill a critical need for drug toxicity data and translational safety intelligence across all stages of drug R&D. 
  • With previously acquired Cortellis, OFF-X will provide critical translational safety intelligence alongside a robust drug pipeline and clinical research information.
  • Beyond Cortellis, OFF-X will strengthen other Clarivate products and services, including the Web of Science, the publisher-independent global citation database. 
  • Clarivate held $2.6 billion in cash and equivalents as of Jun. 30.
  • Price action: CLVT shares closed higher by 1.53% at $23.16 on Tuesday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: M&ANewsTechBriefs